Vicore Pharma

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company headquartered in Stockholm, Sweden, specializing in treatments for rare lung diseases and scarring disorders. The company's principal focus is on unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs) to stabilize or reverse lung function decline. Its lead clinical program, buloxibutid (C21), is an orally available small molecule currently in Phase 2 development for idiopathic pulmonary fibrosis (IPF) and has received Orphan Drug and Fast Track designations from the US FDA. In addition to its traditional drug pipeline, Vicore is developing Almee, a digital therapeutic based on cognitive behavioral therapy to help patients manage the psychological burden of pulmonary fibrosis. The company operates primarily through research partnerships, clinical trials, and licensing arrangements, aiming to bring disease-modifying therapies to specialist lung-care markets globally.